Major cytogenetic aberrations and typical multidrug resistance phenotype of uveal melanoma: Current views and new therapeutic prospects

Cancer Treatment Reviews

Volumn 31, Issue 5, 2005, Pages 361-379

  Baggetto, Loris G ^a   Gambrelle, Joël ^a,b   Dayan, Guila ^a   Labialle, Stéphane ^a,c   Barakat, Stéphane ^a   Michaud, Mickaël ^a   Grange, Jean Daniel ^b   Gayet, Landry ^a  

^a UNIVERSITÉ LYON 1   (France)

^b CROIX ROUSSE HOSPITAL   (France)

^c ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

Cytogenetic; Monosomy 3; Multidrug resistance; P glycoprotein; Prognosis; Uveal melanoma

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CYTARABINE; CYTOTOXIC AGENT; GLYCOPROTEIN P; MESSENGER RNA; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 3; PLATINUM DERIVATIVE; PROTEIN BCL 2; RIBOZYME; SMALL INTERFERING RNA; VINCA ALKALOID;

CANCER GROWTH; CANCER MORTALITY; CANCER RESISTANCE; CANCER RISK; CARCINOGENESIS; CHROMOSOME 3; CHROMOSOME 6P; CHROMOSOME 6Q; CHROMOSOME 8Q; CYTOGENETICS; DRUG UPTAKE; GENE LOSS; GENE OVEREXPRESSION; GENE TARGETING; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC RISK; HUMAN; METASTASIS POTENTIAL; MONOSOMY; MULTIDRUG RESISTANCE; NONVIRAL GENE THERAPY; NUMERICAL CHROMOSOME ABERRATION; PHENOTYPE; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; RISK ASSESSMENT; RNA INTERFERENCE; TRISOMY 8; TUMOR SUPPRESSOR GENE; UVEA MELANOMA;

EID: 26444602486     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ctrv.2005.05.001     Document Type: Article

References (147)

1. Zografos L. Tumeurs intraoculaires, Paris; 2002.
2. R. Becher W.M. Korn G. Prescher Use of fluorescence in situ hybridization and comparative genomic hybridization in the cytogenetic analysis of testicular germ cell tumors and uveal melanomas Cancer Genet Cytogenet 93 1997 22-28
3. L. Kodjikian K. Nguyen L. Lumbroso et al. Familial uveal melanoma: A report on two families and a review of the literature Acta Ophthalmol Scand 81 2003 389-395
4. H.R. Alexander S.K. Libutti D.L. Bartlett et al. A phase I-II study of isolated hepatic perfusion using melphalan with or without tumor necrosis factor for patients with ocular melanoma metastatic to liver Clin Cancer Res 6 2000 3062-3070 3070
5. A.Y. Bedikian S.S. Legha G. Mavligit et al. Treatment of uveal melanoma metastatic to the liver: A review of the M. D. Anderson Cancer Center experience and prognostic factors Cancer 76 1995 1665-1670
6. E.S. Gragoudas K.M. Egan J.M. Seddon et al. Survival of patients with metastases from uveal melanoma Ophthalmology 98 1991 383-389 [discussion 390]
7. U. Keilholz R. Schuster A. Schmittel et al. A clinical phase I trial of gemcitabine and treosulfan in uveal melanoma and other solid tumours Eur J Cancer 40 2004 2047-2052
8. M. Schmidt-Hieber A. Schmittel E. Thiel U. Keilholz A phase II study of bendamustine chemotherapy as second-line treatment in metastatic uveal melanoma Melanoma Res 14 2004 439-442
9. E. Schrock S. du Manoir T. Veldman et al. Multicolor spectral karyotyping of human chromosomes Science 273 1996 494-497 497
10. M. Schena D. Shalon R.W. Davis P.O. Brown Quantitative monitoring of gene expression patterns with a complementary DNA microarray Science 270 1995 467-470 470
11. V.A. White B.K. McNeil L. Thiberville D.E. Horsman Acquired homozygosity (isodisomy) of chromosome 3 during clonal evolution of a uveal melanoma: association with morphologic heterogeneity Genes Chromosomes Cancer 15 1996 138-143
12. F. Tschentscher G. Prescher M. Zeschnigk B. Horsthemke D.R. Lohmann Identification of chromosomes 3, 6, and 8 aberrations in uveal melanoma by microsatellite analysis in comparison to comparative genomic hybridization Cancer Genet Cytogenet 122 2000 13-17
13. N.A. Cross A.K. Murray I.G. Rennie A. Ganesh K. Sisley Instability of microsatellites is an infrequent event in uveal melanoma Melanoma Res 13 2003 435-440
14. P. Parrella D. Sidransky S.L. Merbs Allelotype of posterior uveal melanoma: Implications for a bifurcated tumor progression pathway Cancer Res 59 1999 3032-3037
15. M.R. Speicher G. Prescher S. du Manoir et al. Chromosomal gains and losses in uveal melanomas detected by comparative genomic hybridization Cancer Res 54 1994 3817-3823
16. C.A. Griffin P.P. Long A.P. Schachat Trisomy 6p in an ocular melanoma Cancer Genet Cytogenet 32 1988 129-132 132
17. G. Prescher N. Bornfeld R. Becher Nonrandom chromosomal abnormalities in primary uveal melanoma J Natl Cancer Inst 82 1990 1765-1769
18. K. Sisley I.G. Rennie D.W. Cottam et al. Cytogenetic findings in six posterior uveal melanomas: Involvement of chromosomes 3, 6, and 8 Genes Chromosomes Cancer 2 1990 205-209
19. D.E. Horsman H. Sroka J. Rootman V.A. White Monosomy 3 and isochromosome 8q in a uveal melanoma Cancer Genet Cytogenet 45 1990 249-253
20. K. Sisley D.W. Cottam I.G. Rennie et al. Non-random abnormalities of chromosomes 3, 6, and 8 associated with posterior uveal melanoma Genes Chromosomes Cancer 5 1992 197-200
21. D.E. Horsman V.A. White Cytogenetic analysis of uveal melanoma. Consistent occurrence of monosomy 3 and trisomy 8q Cancer 71 1993 811-819
22. R. Dahlenfors G. Tornqvist K. Wettrell J. Mark Cytogenetical observations in nine ocular malignant melanomas Anticancer Res 13 1993 1415-1420
23. A.D. Singh L. Boghosian-Sell K.K. Wary et al. Cytogenetic findings in primary uveal melanoma Cancer Genet Cytogenet 72 1994 109-115
24. K.B. Gordon C.T. Thompson D.H. Char et al. Comparative genomic hybridization in the detection of DNA copy number abnormalities in uveal melanoma Cancer Res 54 1994 4764-4768
25. M. McNamara C. Felix E.V. Davison M. Fenton S.M. Kennedy Assessment of chromosome 3 copy number in ocular melanoma using fluorescence in situ hybridization Cancer Genet Cytogenet 98 1997 4-8
26. G. Prescher N. Bornfeld H. Hirche et al. Prognostic implications of monosomy 3 in uveal melanoma Lancet 347 1996 1222-1225
27. F. Tschentscher G. Prescher D.E. Horsman et al. Partial deletions of the long and short arm of chromosome 3 point to two tumor suppressor genes in uveal melanoma Cancer Res 61 2001 3439-3442
28. K.A. Patel N.D. Edmondson F. Talbot et al. Prediction of prognosis in patients with uveal melanoma using fluorescence in situ hybridisation Br J Ophthalmol 85 2001 1440-1444
29. K. Sisley I.G. Rennie M.A. Parsons et al. Abnormalities of chromosomes 3 and 8 in posterior uveal melanoma correlate with prognosis Genes Chromosomes Cancer 19 1997 22-28
30. A.G. Scholes B.E. Damato J. Nunn et al. Monosomy 3 in uveal melanoma: correlation with clinical and histologic predictors of survival Invest Ophthalmol Vis Sci 44 2003 1008-1011
31. B. Horsthemke G. Prescher N. Bornfeld R. Becher Loss of chromosome 3 alleles and multiplication of chromosome 8 alleles in uveal melanoma Genes Chromosomes Cancer 4 1992 217-221
32. E. Edstrom E. Mahlamaki B. Nord et al. Comparative genomic hybridization reveals frequent losses of chromosomes 1p and 3q in pheochromocytomas and abdominal paragangliomas, suggesting a common genetic etiology Am J Pathol 156 2000 651-659
33. T. Yamaguchi J. Toguchida T. Yamamuro et al. Allelotype analysis in osteosarcomas: Frequent allele loss on 3q, 13q, 17p, and 18q Cancer Res 52 1992 2419-2423
34. R.N. Wiltshire V.M. Elner T. Dennis A.K. Vine J.M. Trent Cytogenetic analysis of posterior uveal melanoma Cancer Genet Cytogenet 66 1993 47-53
35. V.A. White B.K. McNeil D.E. Horsman Acquired homozygosity (isodisomy) of chromosome 3 in uveal melanoma Cancer Genet Cytogenet 102 1998 40-45
36. M.A. Blasi F. Roccella E. Balestrazzi et al. 3p13 region: A possible location of a tumor suppressor gene involved in uveal melanoma Cancer Genet Cytogenet 108 1999 81-83
37. K. Kok S.L. Naylor C.H. Buys Deletions of the short arm of chromosome 3 in solid tumors and the search for suppressor genes Adv Cancer Res 71 1997 27-92
38. K. Sisley D. Curtis I.G. Rennie R.C. Rees Loss of heterozygosity of the thyroid hormone receptor B in posterior uveal melanoma Melanoma Res 3 1993 457-461
39. A.E. Loercher J.W. Harbour Molecular genetics of uveal melanoma Curr Eye Res 27 2003 69-74
40. K. Satherley L. de Souza M.H. Neale et al. Relationship between expression of topoisomerase II isoforms and chemosensitivity in choroidal melanoma J Pathol 192 2000 174-181
41. N. Myatt P. Aristodemou M.H. Neale et al. Abnormalities of the transforming growth factor-beta pathway in ocular melanoma J Pathol 192 2000 511-518
42. F. Tschentscher J. Husing T. Holter et al. Tumor classification based on gene expression profiling shows that uveal melanomas with and without monosomy 3 represent two distinct entities Cancer Res 63 2003 2578-2584
43. S. Ghazvini D.H. Char S. Kroll F.M. Waldman D. Pinkel Comparative genomic hybridization analysis of archival formalin-fixed paraffin-embedded uveal melanomas Cancer Genet Cytogenet 90 1996 95-101
44. G. Prescher N. Bornfeld R. Becher Two subclones in a case of uveal melanoma. Relevance of monosomy 3 and multiplication of chromosome 8q Cancer Genet Cytogenet 77 1994 144-146
45. G. Prescher N. Bornfeld W. Friedrichs S. Seeber R. Becher Cytogenetics of twelve cases of uveal melanoma and patterns of nonrandom anomalies and isochromosome formation Cancer Genet Cytogenet 80 1995 40-46
46. R. Taub I. Kirsch C. Morton et al. Translocation of the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells Proc Natl Acad Sci USA 79 1982 7837-7841
47. M.D. Cole S.B. McMahon The Myc oncoprotein: A critical evaluation of transactivation and target gene regulation Oncogene 18 1999 2916-2924
48. A.J. Obaya M.K. Mateyak J.M. Sedivy Mysterious liaisons: The relationship between c-Myc and the cell cycle Oncogene 18 1999 2934-2941
49. G.C. Prendergast Mechanisms of apoptosis by c-Myc Oncogene 18 1999 2967-2987
50. E.V. Schmidt The role of c-myc in cellular growth control Oncogene 18 1999 2988-2996
51. C. Mooy K. Vissers G. Luyten et al. DNA flow cytometry in uveal melanoma: The effect of pre-enucleation irradiation Br J Ophthalmol 79 1995 174-177
52. D.J. Blom C.M. Mooy G.P. Luyten et al. Inverse correlation between expression of HLA-B and c-myc in uveal melanoma J Pathol 181 1997 75-79
53. J.S. Chana G.D. Wilson I.A. Cree et al. c-myc, p53, and Bcl-2 expression and clinical outcome in uveal melanoma Br J Ophthalmol 83 1999 110-114
54. J.A. Royds R.M. Sharrard M.A. Parsons et al. C-myc oncogene expression in ocular melanomas Graefes Arch Clin Exp Ophthalmol 230 1992 366-371
55. J.S. Chana I.A. Cree A.J. Foss J.L. Hungerford G.D. Wilson The prognostic significance of c-myc oncogene expression in uveal melanoma Melanoma Res 8 1998 139-144
56. P. Parrella O.L. Caballero D. Sidransky S.L. Merbs Detection of c-myc amplification in uveal melanoma by fluorescent in situ hybridization Invest Ophthalmol Vis Sci 42 2001 1679-1684
57. Y. Aalto L. Eriksson S. Seregard O. Larsson S. Knuutila Concomitant loss of chromosome 3 and whole arm losses and gains of chromosome 1, 6, or 8 in metastasizing primary uveal melanoma Invest Ophthalmol Vis Sci 42 2001 313-317
58. J.M. Karjalainen M.J. Eskelinen J.K. Kellokoski et al. p21 (WAF1/CIP1) expression in stage I cutaneous malignant melanoma: Its relationship with p53, cell proliferation and survival Br J Cancer 79 1999 895-902
59. G. Anastassiou V. Rebmann S. Wagner N. Bornfeld H. Grosse-Wilde Expression of classic and nonclassic HLA class I antigens in uveal melanoma Invest Ophthalmol Vis Sci 44 2003 2016-2019
60. G. Prescher N. Bornfeld B. Horsthemke R. Becher Chromosomal aberrations defining uveal melanoma of poor prognosis Lancet 339 1992 691-692
61. N.C. Naus E. van Drunen A. de Klein et al. Characterization of complex chromosomal abnormalities in uveal melanoma by fluorescence in situ hybridization, spectral karyotyping, and comparative genomic hybridization Genes Chromosomes Cancer 30 2001 267-273
62. D.N. Skilleter R.J. Price G.D. Parnell A.J. Cumber The low uptake of an abrin A-chain immunotoxin by rat hepatic cells in vivo and in vitro Cancer Lett 46 1989 161-166
63. M. Castaing A. Loiseau L. Djoudi Effects of cholesterol on dye leakage induced by multidrug-resistance modulators from anionic liposomes Eur J Pharm Sci 18 2003 81-88
64. R. Castino M. Demoz C. Isidoro Destination 'lysosome': A target organelle for tumour cell killing? J Mol Recognit 16 2003 337-348
65. M. Dietel H. Arps H. Lage A. Niendorf Membrane vesicle formation due to acquired mitoxantrone resistance in human gastric carcinoma cell line EPG85-257 Cancer Res 50 1990 6100-6106
66. E.K. Han S.K. Tahir S.P. Cherian N. Collins S.C. Ng Modulation of paclitaxel resistance by annexin IV in human cancer cell lines Br J Cancer 83 2000 83-88
67. W.T. Beck M.C. Cirtain Continued expression of vinca alkaloid resistance by CCRF-CEM cells after treatment with tunicamycin or pronase Cancer Res 42 1982 184-189
68. J.A. Endicott V. Ling The biochemistry of P-glycoprotein-mediated multidrug resistance Annu Rev Biochem 58 1989 137-171
69. C.J. Chen J.E. Chin K. Ueda et al. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells Cell 47 1986 381-389
70. J.E. Walker M. Saraste M.J. Runswick N.J. Gay Distantly related sequences in the alpha- and beta-subunits of ATP synthase, myosin, kinases and other ATP-requiring enzymes and a common nucleotide binding fold EMBO J 1 1982 945-951
71. C.J. Chen D. Clark K. Ueda et al. Genomic organization of the human multidrug resistance (MDR1) gene and origin of P-glycoproteins J Biol Chem 265 1990 506-514
72. M. Dong F. Penin L.G. Baggetto Efficient purification and reconstitution of P-glycoprotein for functional and structural studies J Biol Chem 271 1996 28875-28883
73. L.S. Kirschner L.M. Greenberger S.I. Hsu et al. Biochemical and genetic characterization of the multidrug resistance phenotype in murine macrophage-like J774.2 cells Biochem Pharmacol 43 1992 77-87
74. C.F. Higgins M.M. Gottesman Is the multidrug transporter a flippase? Trends Biochem Sci 17 1992 18-21
75. M. Demeule J. Jodoin D. Gingras R. Beliveau P-glycoprotein is localized in caveolae in resistant cells and in brain capillaries FEBS Lett 466 2000 219-224
76. Y. Lavie G. Fiucci M. Liscovitch Up-regulation of caveolae and caveolar constituents in multidrug-resistant cancer cells J Biol Chem 273 1998 32380-32383
77. C. Cordon-Cardo J.P. O'Brien J. Boccia et al. Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues J Histochem Cytochem 38 1990 1277-1287
78. F. Thiebaut T. Tsuruo H. Hamada et al. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues Proc Natl Acad Sci USA 84 1987 7735-7738
79. S. Dey J. Patel B.S. Anand et al. Molecular evidence and functional expression of P-glycoprotein (MDR1) in human and rabbit cornea and corneal epithelial cell lines Invest Ophthalmol Vis Sci 44 2003 2909-2918
80. W. Mellado S.B. Horwitz Phosphorylation of the multidrug resistance associated glycoprotein Biochemistry 26 1987 6900-6904
81. J. Posada P. Vichi T.R. Tritton Protein kinase C in adriamycin action and resistance in mouse sarcoma 180 cells Cancer Res 49 1989 6634-6639
82. H.R. Goodfellow A. Sardini S. Ruetz et al. Protein kinase C-mediated phosphorylation does not regulate drug transport by the human multidrug resistance P-glycoprotein J Biol Chem 271 1996 13668-13674
83. r 170,000 to 180,000 glycoprotein specific to multidrug-resistant tumor cells: Effects of verapamil, trifluoperazine, and phorbol esters Cancer Res 47 1987 2860-2865
84. K. Ueda M.M. Cornwell M.M. Gottesman et al. The mdr1 gene, responsible for multidrug-resistance, codes for P-glycoprotein Biochem Biophys Res Commun 141 1986 956-962
85. D.F. Callen E. Baker R.N. Simmers R. Seshadri I.B. Roninson Localization of the human multiple drug resistance gene, MDR1, to 7q21.1 Hum Genet 77 1987 142-144
86. Roninson IBA-P-IA-G-MM. Isolation and characterization of the human MDR (P-Glycoprotein) genes. In: Roninson IB, editor. Molecular and cellular biology of multidrug resistance in tumor cells. Plenum Press; 1991+ADs 1991. p. 91-116.
87. I. Pastan M.M. Gottesman K. Ueda et al. A retrovirus carrying an MDR1 cDNA confers multidrug resistance and polarized expression of P-glycoprotein in MDCK cells Proc Natl Acad Sci USA 85 1988 4486-4490
88. A.M. van der Bliek P. Borst Multidrug resistance Adv Cancer Res 52 1989 165-203
89. F. Baskin R.N. Rosenberg V. Dev Correlation of double-minute chromosomes with unstable multidrug cross-resistance in uptake mutants of neuroblastoma cells Proc Natl Acad Sci USA 78 1981 3654-3658
90. J.L. Biedler T.D. Chang K.W. Scotto P.W. Melera B.A. Spengler Chromosomal organization of amplified genes in multidrug-resistant Chinese hamster cells Cancer Res 48 1988 3179-3187
91. K. Ueda I. Pastan M.M. Gottesman Isolation and sequence of the promoter region of the human multidrug-resistance (P-glycoprotein) gene J Biol Chem 262 1987 17432-17436
92. M. van Groenigen L.J. Valentijn F. Baas Identification of a functional initiator sequence in the human MDR1 promoter Biochim Biophys Acta 1172 1993 138-146
93. S.T. Smale D. Baltimore The "initiator" as a transcription control element Cell 57 1989 103-113
94. T.A. Ince K.W. Scotto Differential utilization of multiple transcription start points accompanies the overexpression of the P-glycoprotein-encoding gene in Chinese hamster lung cells Gene 156 1995 287-290
95. T.A. Ince K.W. Scotto A conserved downstream element defines a new class of RNA polymerase II promoters J Biol Chem 270 1995 30249-30252
96. S. Labialle L. Gayet E. Marthinet D. Rigal L.G. Baggetto Transcriptional regulation of the human MDR1 gene at the level of the inverted MED-1 promoter region Ann NY Acad Sci 973 2002 468-471
97. S. Labialle G. Dayan L. Gayet et al. New invMED1 element cis-activates human multidrug-related MDR1 and MVP genes, involving the LRP130 protein Nucl Acid Res 32 2004 3864-3876
98. B. Ogretmen A.R. Safa Identification and characterization of the MDR1 promoter-enhancing factor 1 (MEF1) in the multidrug resistant HL60/VCR human acute myeloid leukemia cell line Biochemistry 39 2000 194-204
99. X. Zhong A.R. Safa RNA helicase A in the MEF1 transcription factor complex upregulates the MDR1 gene in multidrug resistant cancer cells J Biol Chem 2004
100. K. Takara K. Takagi M. Tsujimoto N. Ohnishi T. Yokoyama Digoxin up-regulates multidrug resistance transporter (MDR1) mRNA and simultaneously down-regulates steroid xenobiotic receptor mRNA Biochem Biophys Res Commun 306 2003 116-120
101. T.W. Synold I. Dussault B.M. Forman The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux Nat Med 7 2001 584-590
102. S.P. Cole G. Bhardwaj J.H. Gerlach et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line Science 258 1992 1650-1654
103. S.P. Cole K.E. Sparks K. Fraser et al. Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells Cancer Res 54 1994 5902-5910
104. D.R. Hipfner S.D. Gauldie R.G. Deeley S.P. Cole Detection of the M(r) 190,000 multidrug resistance protein, MRP, with monoclonal antibodies Cancer Res 54 1994 5788-5792
105. G.J. Zaman M.J. Flens M.R. van Leusden et al. The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump Proc Natl Acad Sci USA 91 1994 8822-8826
106. N. Krishnamachary M.S. Center The MRP gene associated with a non-P-glycoprotein multidrug resistance encodes a 190-kDa membrane bound glycoprotein Cancer Res 53 1993 3658-3661
107. K.C. Almquist D.W. Loe D.R. Hipfner et al. Characterization of the M(r) 190,000 multidrug resistance protein (MRP) in drug-selected and transfected human tumor cell Cancer Res 55 1995 102-110
108. P. Borst R. Evers M. Kool J. Wijnholds A family of drug transporters: the multidrug resistance-associated proteins J Natl Cancer Inst 92 2000 1295-1302
109. Y. Cui J. Konig J.K. Buchholz et al. Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells Mol Pharmacol 55 1999 929-937
110. S. Haga E. Hinoshita K. Ikezaki et al. Involvement of the multidrug resistance protein 3 in drug sensitivity and its expression in human glioma Jpn J Cancer Res 92 2001 211-219
111. M. Kool M. van der Linden M. de Haas F. Baas P. Borst Expression of human MRP6, a homologue of the multidrug resistance protein gene MRP1, in tissues and cancer cells Cancer Res 59 1999 175-182
112. J. Renes E.G. de Vries P.L. Jansen M. Muller The (patho)physiological functions of the MRP family Drug Resist Updat 3 2000 289-302
113. D.W. Loe K.C. Almquist R.G. Deeley S.P. Cole Multidrug resistance protein (MRP)-mediated transport of leukotriene C4 and chemotherapeutic agents in membrane vesicles. Demonstration of glutathione-dependent vincristine transport J Biol Chem 271 1996 9675-9682
114. A. Lorico G. Rappa R.A. Finch et al. Disruption of the murine MRP (multidrug resistance protein) gene leads to increased sensitivity to etoposide (VP-16) and increased levels of glutathione Cancer Res 57 1997 5238-5242
115. A. Lorico G. Rappa R.A. Flavell A.C. Sartorelli Double knockout of the MRP gene leads to increased drug sensitivity in vitro Cancer Res 56 1996 5351-5355
116. R. Evers M. Kool L. van Deemter et al. Drug export activity of the human canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2) cDNA J Clin Invest 101 1998 1310-1319
117. G.L. Scheffer P.L. Wijngaard M.J. Flens et al. The drug resistance-related protein LRP is the human major vault protein Nat Med 1 1995 578-582
118. Q. Zhu M.S. Center Cloning and sequence analysis of the promoter region of the MRP gene of HL60 cells isolated for resistance to adriamycin Cancer Res 54 1994 4488-4492
119. E.M. Leslie R.G. Deeley S.P. Cole Toxicological relevance of the multidrug resistance protein 1, MRP1 (ABCC1) and related transporters Toxicology 167 2001 3-23
120. Y.P. Lu Z.S. Li Y.M. Drozdowicz et al. AtMRP2, an Arabidopsis ATP binding cassette transporter able to transport glutathione S-conjugates and chlorophyll catabolites: Functional comparisons with Atmrp1 Plant Cell 10 1998 267-282
121. R.J. Scheper H.J. Broxterman G.L. Scheffer et al. Overexpression of a M(r) 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance Cancer Res 53 1993 1475-1479
122. V.A. Kickhoefer S.K. Vasu L.H. Rome Vaults are the answer, what is the question Trends Cell Biol 6 1996 174-178
123. S. Akiyama Z.S. Chen M. Kitazono et al. Mechanisms for resistance to anticancer agents and the reversal of the resistance Hum Cell 12 1999 95-102
124. S. Meschini M. Marra A. Calcabrini et al. Role of the lung resistance-related protein (LRP) in the drug sensitivity of cultured tumor cells Toxicol In Vitro 16 2002 389-398
125. M.A. Izquierdo A.G. van der Zee J.B. Vermorken et al. Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma J Natl Cancer Inst 87 1995 1230-1237
126. Y. Aritas O. Kara B. Abdulkadir O. Sakrak The importance of the tumor basement membrane laminin and LRP/MVP receptors in breast cancer Breast J 9 2003 339-340 340
127. M. Kitazono T. Sumizawa Y. Takebayashi et al. Multidrug resistance and the lung resistance-related protein in human colon carcinoma SW-620 cells J Natl Cancer Inst 91 1999 1647-1653
128. M.H. Mossink A. van Zon E. Franzel-Luiten et al. Disruption of the murine major vault protein (MVP/LRP) gene does not induce hypersensitivity to cytostatics Cancer Res 62 2002 7298-7304
129. A.C. Siva S. Raval-Fernandes A.G. Stephen et al. Up-regulation of vaults may be necessary but not sufficient for multidrug resistance Int J Cancer 92 2001 195-202
130. W. Berger S. Spiegl-Kreinecker J. Buchroithner et al. Overexpression of the human major vault protein in astrocytic brain tumor cells Int J Cancer 94 2001 377-382
131. D.R. Mercatante J.L. Mohler R. Kole Cellular response to an antisense-mediated shift of Bcl-x pre-mRNA splicing and antineoplastic agents J Biol Chem 277 2002 49374-49382
132. C. Morassutti B. Scaggiante L.E. Xodo et al. Reduction of mdr1 gene amplification in human multidrug-resistant LoVo DX cell line is promoted by triple helix-forming oligonucleotides Antisense Nucl Acid Drug Dev 9 1999 261-270
133. H. Hatanaka Y. Abe M. Naruke et al. Modulation of multidrug resistance in a cancer cell line by anti-multidrug resistance-associated protein (MRP) ribozyme Anticancer Res 21 2001 879-885
134. E. Marthinet G. Divita J. Bernaud D. Rigal L.G. Baggetto Modulation of the typical multidrug resistance phenotype by targeting the MED-1 region of human MDR1 promoter Gene Ther 7 2000 1224-1233
135. A. Bielinska R.A. Shivdasani L.Q. Zhang G.J. Nabel Regulation of gene expression with double-stranded phosphorothioate oligonucleotides Science 250 1990 997-1000
136. C. Nieth A. Priebsch A. Stege H. Lage Modulation of the classical multidrug resistance (MDR) phenotype by RNA interference (RNAi) FEBS Lett 545 2003 144-150
137. H. Wu W.N. Hait J.M. Yang Small interfering RNA-induced suppression of MDR1 (P-glycoprotein) restores sensitivity to multidrug-resistant cancer cells Cancer Res 63 2003 1515-1519
138. G. Reid P. Wielinga N. Zelcer et al. The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs Proc Natl Acad Sci USA 100 2003 9244-9249
139. M. McNamara M. Clynes B. Dunne et al. Multidrug resistance in ocular melanoma Br J Ophthalmol 80 1996 1009-1012
140. J.P. van der Pol D.J. Blom M.J. Flens et al. Multidrug resistance-related proteins in primary choroidal melanomas and in vitro cell lines Invest Ophthalmol Vis Sci 38 1997 2523-2530
141. S. Chevillard P. Vielh P. Vallidire J. Robert J.P. Marie A study of the expression of MDR1 gene in solid tumors. Initial results of a multicenter evaluation Bull Cancer 83 1996 626-633
142. G.G. McGill M. Horstmann H.R. Widlund et al. Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability Cell 109 2002 707-718
143. J.C. Reed Dysregulation of apoptosis in cancer J Clin Oncol 17 1999 2941-2953
144. R. Grover G.D. Wilson Bcl-2 expression in malignant melanoma and its prognostic significance Eur J Surg Oncol 22 1996 347-349
145. B. Jansen V. Wacheck E. Heere-Ress et al. Chemosensitisation of malignant melanoma by BCL2 antisense therapy Lancet 356 2000 1728-1733
146. J.W. Harbour L. Worley D. Ma M. Cohen Transducible peptide therapy for uveal melanoma and retinoblastoma Arch Ophthalmol 120 2002 1341-1346
147. S. Labialle L. Gayet E. Marthinet D. Rigal L.G. Baggetto Transcriptional regulators of the human multidrug resistance 1 gene: Recent views Biochem Pharmacol 64 2002 943-948